TABLE 4.
Association between gut bacterial genera at the end of placebo period and urinary ENL and END excretion after 60 d of lignan extract (n = 38)1
| Bacterial taxon | n (%) of 38 participants harboring each genus | Direction of association2 | P value |
|---|---|---|---|
| ENL | |||
| Bacteria; Bacteroidetes; Bacteroidia; Bacteroidales; Rikenellaceae; Alistipes | 37 (97) | + | 0.0013 |
| Bacteria; Proteobacteria; Alphaproteobacteria; Rhodospirillales; uncultured; uncultured bacterium | 5 (13) | + | 0.004 |
| Bacteria; Firmicutes; Clostridia; Clostridiales; Ruminococcaceae; Ruminococcus2 | 21 (55) | + | 0.01 |
| Bacteria; Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; [Eubacterium] xylanophilum group | 14 (37) | + | 0.015 |
| Archaea; Euryarcheota; Methanobacteria; Methanobacteriales; Methanobacteriaceae; Methanobrevibacter | 22 (61) | + | 0.015 |
| Bacteria; Firmicutes; Clostridia; Clostridiales; Ruminococcaceae; UBA1819 | 7 (18) | − | 0.024 |
| Bacteria; Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; Roseburia | 38 (100) | + | 0.026 |
| Bacteria; Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; Coprococcus3 | 17 (45) | − | 0.034 |
| Bacteria; Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; CAG-56 | 5 (13) | − | 0.039 |
| Bacteria; Proteobacteria; Deltaproteobacteria; Desulfovibrionales; Desulfovibrionaceae; Bilophila | 13 (34) | − | 0.040 |
| Bacteria; Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; [Ruminococcus] gnavus group | 9 (24) | − | 0.048 |
| Bacteria; Firmicutes; Clostridia; Clostridiales; Lachnospiraceae; Dorea | 38 (100) | − | 0.049 |
| END | |||
| Bacteria; Cyanobacteria; Melainabacteria; Gastranaerophilales; uncultured_bacterium; Other | 4 (11) | − | 0.023 |
| Bacteria; Bacteroidetes; Bacteroidia; Bacteroidales; Barnesiellaceae; Barnesiella | 20 (53) | + | 0.034 |
| Bacteria; Firmicutes; Clostridia; Clostridiales; Ruminococcaceae; CAG-352 | 6 (16) | + | 0.043 |
1
Results from linear regression models for the association of urinary enterolignan excretion (continuous) after lignan intervention with each genus abundance at the end of placebo period, adjusted for sex, BMI, and age; only genera significant at P < 0.05 are listed. END, enterodiol; ENL, enterolactone.
2
+, higher relative abundance in high- compared with low-ENL excreters; −, lower relative abundance in high- compared with low-ENL excreters.
3
Significant with Benjamini-Hochberg false discovery rate (<0.1 for 80 tests within each analysis for ENL and END).